$2.22-3.3%Nov 13 close
Figures through September 30, 2026, from the 10-Q filed November 12, 2026
Just reported
From Macrogenics, Inc.'s results release of November 12, 2026; its quarterly report has since been filed.
Actual
$18.7M
-65% y/y
-43% q/q
Guided
—
No guide given
Actual
-$0.32
Guided
—
No guide given
Actual
-$20.3M
| Measure | 3 months toSep 30, 2026 | 3 months toSep 30, 2025 | Change |
|---|---|---|---|
| Total Revenue | $18.7M | $53M | -64.78% |
| Profit | -$20.1M | $16.8M | -219.34% |
| Profit per share | -$0.32 | $0.27 | -218.52% |
| Free Cash Flow | -$6.4M | -$30.6M | +79.08% |
These are single quarters, not a trailing year — the figures elsewhere on this site cover twelve months and will be much larger. A seasonal business swings a long way between the two: ServiceNow earns $2.0B of free cash flow in its December quarter and $0.5B in its June one.
Compared against the same quarter a year earlier, not against an analyst forecast. A “beat” or “miss” needs a consensus estimate, which is licensed data we do not carry — and getting it wrong is worse than leaving it out.
Macrogenics, Inc. reported on November 12, 2026. We are fetching the call transcript; its summary follows once the transcript is in.
“MacroGenics has made significant progress over the past year. We have strengthened our business, sharpened our pipeline development priorities, delivered on key strategic objectives and generated approximately $290 million in non-dilutive capital over the past 12 months,”
Quoted verbatim from the release, and shown only when the filing attributes it to a named person.
Releases land before the open or after the close, so the window runs from the close before the report day to the close of the session after it — the reaction is inside it either way.
Inc. MacroGenics (the Company) is a clinical-stage biopharmaceutical company focused on developing innovative monoclonal antibody-based therapeutics for the treatment of cancer. The Company generates its pipeline of product candidates primarily from its proprietary suite of next-generation antibody-based technology platforms, which have applicability across broad therapeutic domains. The combination of MacroGenics' technology platforms and protein engineering expertise has allowed the Company to generate promising product candidates and enter into several strategic collaborations with global pharmaceutical and biotechnology companies.
The company’s own description, as it appears at the foot of the release.
The quote and the company description come from Macrogenics, Inc.’s Item 2.02 8-K filed November 12, 2026; the table is built from its quarterly reports. Read the release on EDGAR Share prices are split- and dividend-adjusted.
Guided
—
No guide given
Set against the company's own guidance and the same quarter a year earlier, not analysts' estimates, which we do not hold. Adjusted figures are the company's own non-GAAP measures, as stated in the release.